Vaxcyte, Inc.
PCVXCIK 0001649094 · Biological Products, (No Diagnostic Substances) · Nasdaq
- SutroVax, Inc. (until 2020-04-03)
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$840.74M
−65.2% YoY
Q1 May 2026
EPS Diluted (TTM)
−$6.12
−48.2% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$672.53M
Q1 May 2026
Cash
$260.84M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
144.4M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.